Study drug plus docetaxel for advanced triple-negative breast cancer
Part of Cancer, Skin clinical trials.
This Phase 1/2 study tests a new oral drug (BLEX 404) together with docetaxel to see how safe it is and how well it works for people with advanced or metastatic triple-negative breast cancer. If you qualify, you would receive docetaxel by plan and also take BLEX 404 by mouth each day.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman age 20 to 70, and you can sign the consent form
- Your breast cancer is “triple-negative” (ER 10% or less, PR 10% or less, and HER2 is negative)
- Your general condition is good enough for treatment (ECOG 0 to 2)
- Your blood counts, liver tests, and kidney tests meet study limits
- You can use effective birth control if you could become pregnant (and avoid pregnancy during the study and after)
- You must be planning to receive docetaxel as the main cancer medicine in this study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 study tests whether a special form of docetaxel (a chemotherapy drug) works better and is safe for people with triple-negative breast cancer that has spread or grown locally. You may be eligible if your cancer is triple-negative and you have measurable disease that can be tracked on scans, along with adequate organ and heart function.
This trial tests a new personalized treatment approach (mRNA-lncRNA model) for people with low-risk, early-stage triple-negative breast cancer who have already had surgery. It aims to see if a less intense treatment can work just as well as standard care.
This trial tests an oral form of a common chemo drug, paclitaxel, given before surgery for triple-negative breast cancer. It aims to find the best dose and see how well it shrinks tumors.
This study tests a new drug combination (BL-B01D1 plus an immunotherapy) for people with advanced triple-negative breast cancer who have not had prior treatment for their advanced disease. The goal is to see if the combination works better at shrinking or controlling the cancer.
This Phase 2 trial compares two chemotherapy combinations to see which works better for advanced triple-negative breast cancer. You would be asked to join one treatment arm based on study assignment and be followed for response and side effects.
This Phase 2 trial tests a treatment for people with triple-negative breast cancer that has come back or spread and has continued to progress despite earlier therapies. It may help by trying a new approach in patients who still have enough health to safely receive more treatment.
Hear when a new Triple Negative Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.